Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Use of Inhaled corticosteroid (ICS)-containing regimen for COPD patients with high or low blood eosinophilia: A meta-analysis Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018
Association between blood eosinophil count and risk of exacerbations in patients with COPD Source: International Congress 2017 – Biomarker-based asthma control Year: 2017
One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002
Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study Source: International Congress 2018 – Eosinophils in airway disease Year: 2018
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis Source: Eur Respir J 2014; 44: 789-791 Year: 2014
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Patients with COPD prescribed inhaled corticosteroid in primary care – Time for re-assessment based on exacerbation rate and blood eosinophils? Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care Year: 2020
Blood eosinophils as a marker of response to inhaled corticosteroids in COPD Source: Eur Respir J 2016; 47:1374-1382 Year: 2016
The interrelationship of the inflammatory markers in blood and sputum of stable COPD patients before and after treatment with inhaled steroids and N-acetylcysteine Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003
Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids Source: Eur Respir J 2002; 20: 1364-1369 Year: 2002
Sputum eosinophil counts in a large population of mild-to-moderate asthmatics: distribution, relationship with methacholine bronchial responsiveness and influence of a regular treatment with low doses of inhaled corticosteroids Source: Eur Respir J 2001; 18: Suppl. 33, 531s Year: 2001
Peripheral blood eosinophil counts in COPD patients and its relationship with prescription of inhaled corticosteroid in real world setting in Japan. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010
Impact on steroid dosing after introducing sputum eosinophils count into a severe asthma clinic Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Low adherence to inhaled corticosteroids/long-acting ß2 -agonists and biologic treatment in severe asthmatics Source: ERJ Open Res, 6 (2) 00017-2020; 10.1183/23120541.00017-2020 Year: 2020
Risks of pneumonia in asthmatic patients taking inhaled corticosteroids Source: Annual Congress 2010 - Management of airway disease Year: 2010
High sputum eosinophils are associated with better response to inhaled corticosteroids in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002